Extrawell Pharmaceutical Holdings Ltd
00858
Company Profile
Business description
Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing, Trading, and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. Geographically, it derives a majority of its revenue from China.
Contact
979 King’s Road
Suites 2206-08, 22nd Floor
Devon House, Taikoo Place
Quarry Bay
Hong Kong
HKGT: +852 28561918
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
161
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,731.13 | 4.93 | 0.06% |
| DAX 40 | 22,573.62 | 80.24 | -0.35% |
| Dow JONES (US) | 46,264.68 | 56.21 | 0.12% |
| FTSE 100 | 9,932.30 | 38.15 | 0.39% |
| HKSE | 25,063.71 | 681.24 | 2.79% |
| NASDAQ | 21,824.88 | 121.88 | -0.56% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 197.97 | -1.53% |
| S&P 500 | 6,575.30 | 5.70 | -0.09% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |